mRNA 癌症疫苗的全球市场：临床试验与未来展望（2024 年）

Global mRNA Cancer Vaccines Clinical Trials & Market Future Outlook 2024

出版日期: 2024年06月01日 | 出版商:

KuicK Research | 英文 160 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

自从使用 mRNA 疫苗来治疗冠状病毒的那些令人兴奋的日子以来，2019 年临床研究人员正在努力利用 mRNA 疫苗来治疗癌症疾病。基于mRNA疫苗治疗冠状病毒的胜利，许多研究人员认为尖端的mRNA疫苗由于其独特的作用机制可以用于治疗癌症患者。因此，mRNA癌症疫苗市场预计在未来几年将进一步扩大。目前该领域的研发市场存在于美国和中国，但其他地区如欧洲国家也是新兴地区，临床前和临床试验证明了这一点。

迄今为止，还没有mRNA 癌症疫苗进入商业化的全球市场，两种mRNA 候选疫苗CMB-305 和mRNA 4157 的结合物正处于后期开发（III 期），鑑于目前的情况，预计会出现突破性的mRNA癌症疫苗。

迄今为止，在这种创新疗法的变革潜力以及研发方面的重大进展的推动下，全球 mRNA 癌症疫苗领域经历了前卫的成长。越来越多的研究表明，mRNA 癌症疫苗具有治疗癌症的潜力，并且表现出更安全、更好的耐受性，从而开闢了新的途径。虽然mRNA癌症疫苗主要用于治疗实体肿瘤，但在不久的将来mRNA疫苗也将用于治疗血癌。

儘管全球市场上mRNA癌症疫苗的开发进展顺利，但它面临许多课题和致命弱点，包括长期疗效和其他治疗方法的竞争。另一方面，临床试验管线强劲，未来mRNA癌症疫苗领域有望迎来狂热的发展，为製药公司推进mRNA癌症疫苗领域提供了机会。

本报告检视了全球 mRNA 癌症疫苗市场，并提供了市场概况，包括药物趋势、临床试验趋势、区域趋势以及进入市场的公司的竞争格局。

mRNA Cancer Vaccines In Clinical Trials: > 60 Vaccines
Highest Phase Of Clinical Trials: Phase III ( 2 Vaccine)
mRNA Cancer Vaccine Clinical Trials Insight By Company, Country, Indication & Phase
First Commercial mRNA Vaccine Approval Expected By 2029
US & China Dominating mRNA Cancer Vaccines Clinical Trials: > 45 Vaccines
mRNA Vaccines For Skin Cancer Dominating Trials: > 10 Vaccines

From that time impetuous when mRNA vaccines were utilized for the management of coronavirus, in 2019, clinical researchers are working insistently with the intention of using mRNA vaccines for the treatment of cancer ailments. Building on the triumph of mRNA vaccine to cure coronavirus, copious researchers believed that cutting edge mRNA vaccines can be used to treat cancer patients owing to its exclusive mode of action. For that reason, it can be forecast that the market for mRNA cancer vaccine is expected to advance further in the imminent years. Currently, the market for this segment exists in the US coupled with China in terms of research and development; however, other regions, like European countries, are also an emerging area as evident from preclinical and clinical studies.

Until now, no mRNA cancer vaccines have entered into the commercial global market, with 2 mRNA vaccines contenders, CMB-305 in conjugation with mRNA 4157, being in the late phase of development (phase III), it can be prophesied that first breakthrough mRNA cancer vaccine will enter into the global market in upcoming 5-7 years and we contemplates that the casement of first mRNA cancer vaccine will result in an overall revenue of US$ 100 Million after its approval within 12-18 months. According to KuicK Research recent study on global mRNA clinical landscape, 3 to 4 mRNA cancer vaccines are likely to commercially enter the market in following decennium. As well as, with cumulative sales clenches plausibility of more than US$ 5 Billion in years to come.

For that reason, several mRNA cancer vaccines preclinical and clinical trials are ongoing in the domain. For instance, The V Foundation for Cancer Research in collaboration with University of Florida are planning to initiate a phase I/II clinical trial in order to examine the safety as well as immunologic activity of RNA lipid Particle (RNA-LP) Vaccines in patients with recurrent pulmonary osteosarcoma. It is an interventional study, which has an estimated study start date in August 2024 and is projected to be complete by October 2026.

Above this, the domain of mRNA cancer vaccine is experiencing trailblazing growth due to increasing research collaboration, and investments. For instance, in June 2024, Moderna has joined hands with Merck by announcing 3 year data for mRNA-4157 (V940) in combination with Keytruda (pembrolizumab) which established sustained improvement in patients suffering from high-risk stage III/IV melanoma following complete resection. Moreover, the University of Texas MD Anderson Cancer Center in addition to CureVac N.V. proclaimed a co-development along with licensing agreement in order develops novel mRNA-based cancer vaccines in April 2024.

Coupled with collaborations, advancement in technological and drug delivery is also another aspect which is influencing global mRNA cancer vaccine growth. For instance, in August 2023, healthcare professionals from Johns Hopkins Medicine have developed a nanoparticle based design which clenches plausibility to enhance mRNA cancer vaccine delivery.

Hitherto, the global sector of mRNA cancer vaccine has acknowledged an avant-garde growth, fueled by the noteworthy progression in research and development, in addition to the transformative potential of this innovative treatment modality. Accumulating studies have revealed that mRNA cancer vaccines clenches potential of treating cancer and exemplifies safer as well as well tolerated profile, thereby, offering novel avenue. Albeit, mRNA cancer vaccines are predominately used to treat solid tumors; nonetheless, treatment of hematological cancer malignancies by mRNA vaccines are likewise to be utilized in imminent years.

There is a favorable prospect in addition to development mRNA cancer vaccine in the global market but with a number of hardships and Achilles heels, like long term effectiveness and competition from other therapies. In the meantime, there exists a robust and cumbersome pipeline of clinical trials; hence, it is expected that the realm of mRNA cancer vaccine clenches enthusiastic forthcoming; representing an opportunity for pharma companies to advance the realm of mRNA cancer vaccine.

1. mRNA Vaccines as Next Generation Cancer Immunotherapy

1.1 mRNA Vaccines Overview
1.2 mRNA Vaccines v/s Other Cancer Therapeutic Approaches
1.3 mRNA Vaccines v/s Other Vaccines

2. Global mRNA Cancer Vaccine Clinical Trials Insight By Company, Country, Indication & Phase

2.1 Research
2.2 Preclinical
2.3 Phase I
2.4 Phase I/II
2.5 Phase II
2.6 Phase II/III
2.7 Phase III

3. Global Cancer mRNA Vaccines Clinical Pipeline Overview

3.1 By Company
3.2 By Country
3.3 By Indication
3.4 By Patient Segment
3.5 By Phase
3.6 By Priority Status

4. Global mRNA Cancer Vaccines Market Overview

4.1 Current Market Trends
4.2 Future Market Commercialization & Clinical Opportunities

5. Global mRNA Cancer Vaccines Market Trends by Country

5.1 US
5.2 China
5.3 Australia
5.4 Europe
5.5 Canada
5.6 UK

6. Global mRNA Cancer Vaccines Clinical Landscape by Indication

6.1 Breast Cancer
6.2 Brain Cancer
6.3 Melanoma
6.4 Colorectal Cancer
6.5 Head & Neck Cancers
6.6 Lung Cancer
6.7 Cervical Cancer
6.8 Digestive System Cancer

7. Global mRNA Cancer Vaccines Market Collaborations, Deals & Investments

8. Proprietary Technologies & Methodologies for mRNA Cancer Vaccine Development

8.1 FixVac - BioNTech
8.2 iNeST - BioNTech
8.3 NanoReady - Samyang Holdings
8.4 CureVac Method - CureVac
8.5 mRNA platform - Moderna
8.6 NeoCura Ag - NeoCura
8.7 OligoPhore(TM) and SemaPhore(TM) - Altamira Therapeutics
8.8 mRNA Medicines Platform & Proprietary LNP Delivery Technology - Providence

Therapeutic

8.9 RNAimmune

9. Competitive Landscape

9.1 BioNTech
9.2 Combined Therapeutics
9.3 CureVac
9.4 EpiVax
9.5 HDT Bio
9.6 Immorna
9.7 Immune Design
9.8 MDimune
9.9 Moderna Therapeutics
9.10 NeoCura
9.11 pHion Therapeutics
9.12 Providence Therapeutics
9.13 Regen BioPharma
9.14 RNAimmune
9.15 TransCode Therapeutics

简介目录图表

List of Figures

Figure 3-1: Global - mRNA Cancer Vaccines Clinical Pipeline by Company (Numbers), 2024
Figure 3-2: Global - mRNA Cancer Vaccines Clinical Pipeline by Country (Numbers), 2024
Figure 3-3: Global - mRNA Cancer Vaccines Clinical Pipeline by Indication (Numbers), 2024
Figure 3-4: Global - mRNA Cancer Vaccines Clinical Pipeline by Patient Segment (Numbers), 2024
Figure 3-5: Global - mRNA Cancer Vaccines Clinical Pipeline by Phase (Numbers), 2024
Figure 3-6: Global - mRNA Cancer Vaccines Clinical Pipeline by Priority Status (Numbers), 2023
Figure 6-1: KEYNOTE-603 Phase I (NCT03313778) Study - Initiation & Completion Year
Figure 6-2: Autogene Cevumeran Phase I (NCT03289962) Study - Initiation & Completion Year
Figure 6-3: CVGBM Phase I (NCT05938387) Study - Initiation & Completion Year
Figure 6-4: Autogene Cevumeran Phase I (NCT03289962) Study - Initiation & Completion Year
Figure 6-5: BNT111 Phase I (NCT04526899) Study - Initiation & Completion Year
Figure 6-6: mRNA-4157 Phase II (NCT03897881) Study - Initiation & Completion Year
Figure 6-7: mRNA-4157 Phase III (NCT05933577) Study - Initiation & Completion Year
Figure 6-8: BNT122 Phase II (NCT04486378) Study - Initiation & Completion Year
Figure 6-9: BNT113 Phase II (NCT04534205) Study - Initiation & Completion Year
Figure 6-10: mRNA-4157 Phase I (NCT03313778) Study - Initiation & Completion Year
Figure 6-11: BI1361849 Phase I/II (NCT03164772) Study - Initiation & Completion Year
Figure 6-12: V940 Phase III (NCT06077760) Study - Initiation & Completion Year
Figure 6-13: Autogene cevumeran Phase I (NCT04161755) Study - Initiation & Completion Year
Figure 6-14: Autogene cevumeran Phase II (NCT05968326) Study - Initiation & Completion Year
Figure 8-1: BioNTech - uRNA products
Figure 8-2: BioNTech - iNeST technology
Figure 8-3: CureVac - CureVac Method for Generation of mRNA Therapeutics
Figure 8-4: Moderna - mRNA Technology
Figure 8-5: NeoCura - NeoCura Ag Platform
Figure 8-6: Providence Therapeutic - mRNA Medicines Platform Benefits

List of Tables

Table 1-1: mRNA Vaccines v/s Other Cancer Therapeutic Approaches
Table 1-2: mRNA-Based Cancer Vaccines vs. Other Cancer Vaccines
Table 4-1: Regulatory Designations Granted to Investigational mRNA Cancer Vaccines
Table 5-1: Europe - Ongoing Clinical Trials for mRNA Cancer Vaccines
Table 5-2: UK - Ongoing Clinical Trials for mRNA Cancer Vaccines
Table 6-1: Breast Cancer - Some mRNA Vaccines in Clinical Trials
Table 6-2: Brain Cancer - Some mRNA Vaccines in Clinical Trials
Table 6-3: Melanoma - Some mRNA Vaccines in Clinical Trials
Table 6-4: Colorectal Cancer - Some mRNA Vaccines in Clinical Trials
Table 6-5: Head & Neck Cancer mRNA Vaccines in Clinical Trials
Table 6-6: Lung Cancer - Some mRNA Vaccines in Clinical Trials
Table 6-7: Cervical Cancer - Some mRNA Vaccines in Clinical Trials
Table 6-8: Digestive System Cancers - Some mRNA Vaccines in Clinical Trials